Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Antiviral drug resistance

Article Abstract:

The first report of cytomegalovirus (CMV) resistance to the drug ganciclovir occurred in 1989. All three patients had been taking the drug for a relatively long period of time. CMV was first reported to be resistant to foscarnet in 1991, and in 1995, several CMV strains were found that were resistant to both drugs. The most common assays used to detect drug resistance are the plaque reduction assay and a DNA hybridization assay. However, they can give different results so standards are needed. Mutations in the viral UL97 and UL54 genes are the most common cause of resistance.

Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1996

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Current knowledge base, trends, and current thinking

Article Abstract:

In 1995, four cytomegalovirus (CMV) isolates from four different patients were found to be resistant to ganciclovir and foscarnet, the two approved drugs for CMV infection. All of the isolates had mutations in the viral genes UL97 and pol. Research on these strains indicates that they all developed from the same strain and the mutations were added as the strain evolved. However, drug resistance is still uncommon, occurring in fewer than 1% of patients taking drugs to prevent CMV and in 8% of those who take the drugs to treat CMV infection.

Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1996

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Background

Article Abstract:

Many healthy adults have been exposed to cytomegalovirus (CMV) by the time they reach middle age, but most do not develop disease. This is not true in people who have damaged immune systems, such as those with HIV infection or those receiving an organ transplant. These patients can develop serious CMV disease. The only drugs approved by the FDA to treat CMV infection are ganciclovir and foscarnet. Both are very effective in treating CMV infection and ganciclovir is also effective in preventing infection.

Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1996
Complications and side effects, HIV infection, Drug therapy, HIV infections, Cytomegalovirus infections, Transplantation of organs, tissues, etc., Organ transplantation, Tissue transplantation, Transplantation

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Health aspects, Analysis, Drug resistance in microorganisms, Microbial drug resistance, Ganciclovir, Cytomegaloviruses, Cytomegalovirus, Foscarnet
Similar abstracts:
  • Abstracts: Parents' knowledge of the purposes and content of preparticipation physical examinations. Clinician agreement on physical findings in child sexual abuse cases
  • Abstracts: Drivers: avoid drugs to stay alert. Plane safety: what airlines do to stay safe on the ground and in the air. Say no to booze and drugs in your workplace
  • Abstracts: A 61-year-old man with Parkinson's disease. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions
  • Abstracts: When training is a world apart. Nurse, there's a fly on my wall. An education bullying: bullying does more than frighten children. It can cause frequent headaches, bed-wetting and even sever abdominal pain, school nurses have discovered
  • Abstracts: A randomized trial comparing aerobic exercise and resistance exercise with a health education program in older adults with knee osteoarthritis: the Fitness Arthritis and Seniors Trial (FAST)
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.